Aaron G.L. Fletcher - Jun 13, 2025 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Role
10%+ Owner
Signature
Aaron G.L. Fletcher By: /s/ John Fucci, as attorney-in-fact
Stock symbol
LTRN
Transactions as of
Jun 13, 2025
Transactions value $
-$123,600
Form type
4
Date filed
6/13/2025, 07:57 PM
Previous filing
Jun 13, 2025
Next filing
Jun 20, 2025

Reporting Owners (10)

Name Relationship Address Signature Signature date CIK
Fletcher Aaron G.L. 10%+ Owner C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH Aaron G.L. Fletcher By: /s/ John Fucci, as attorney-in-fact 2025-06-13 0001789490
BIOS Fund I, LP 10%+ Owner C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH Bios Fund I, LP By: Bios Equity Partners, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 2025-06-13 0001697316
BIOS Fund I QP, LP 10%+ Owner C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH Bios Fund I QP, LP By: Bios Equity Partners, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 2025-06-13 0001700297
BIOS Fund II, LP 10%+ Owner C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH Bios Fund II, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 2025-06-13 0001714576
BIOS Fund II QP, LP 10%+ Owner C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH Bios Fund II QP, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 2025-06-13 0001716869
BIOS Fund II NT, LP 10%+ Owner C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH Bios Fund II NT, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 2025-06-13 0001728851
Bios Equity Partners, LP 10%+ Owner C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH Bios Equity Partners, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 2025-06-13 0001813314
Bios Equity Partners II, LP 10%+ Owner C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH Bios Equity Partners II, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 2025-06-13 0001813313
BIOS Capital Management, LP 10%+ Owner C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH Bios Capital Management, LP By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 2025-06-13 0001813845
BIOS Advisors GP, LLC 10%+ Owner C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH Bios Advisors GP, LLC By: /s/ John Fucci, as attorney-in-fact 2025-06-13 0001813844

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LTRN Common Stock Sale -$22.3K -7.21K -3.67% $3.09 189K Jun 13, 2025 By Bios Fund I QP, LP F1, F2, F3, F4
transaction LTRN Common Stock Sale -$38.1K -12.3K -3.67% $3.09 323K Jun 13, 2025 By Bios Fund I, LP F1, F2, F3, F4
transaction LTRN Common Stock Sale -$5.88K -1.9K -3.67% $3.09 50K Jun 13, 2025 By Bios Fund II NT, LP F1, F2, F3, F4
transaction LTRN Common Stock Sale -$43.9K -14.2K -3.67% $3.09 373K Jun 13, 2025 By Bios Fund II QP, LP F1, F2, F3, F4
transaction LTRN Common Stock Sale -$13.5K -4.35K -3.67% $3.09 114K Jun 13, 2025 by Bios Fund II, LP F1, F2, F3, F4
holding LTRN Common Stock 26.1K Jun 13, 2025 By BP Directors, LP F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Aaron G.L. Fletcher is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management.
F3 Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
F4 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Remarks:

This Form 4 is the first of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting person. The second Form 4 will be filed by Leslie W. Kreis as the designated filer.